Not Yet Recruiting PHASE3 INTERVENTIONAL 2-arm NCT06925698

Immunosuppressive Therapy Alone Versus Plus Oral Anticoagulation in the Treatment of VT Associated With Behcet's Disease (BETTER)

Immunosuppressive Therapy Alone Versus Immunosuppressive Therapy Plus Oral Anticoagulation in the Treatment of Lower Extremity Venous Thrombosis Associated With Behcet's Disease

Sponsor: Health Institutes of Turkey

Conditions Behcet Disease Behcet Disease and Vascular Involvement Deep Venous Thromboses Post Thrombotic Syndrome

Interventions Placebo plus immunosuppression Rivaroxaban plus immunosupression

Updated 2 times since 2025 Last updated: Apr 7, 2025 Started: Apr 30, 2025 Primary completion: Apr 1, 2027 Completion: Apr 1, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Behcet Disease and Behcet Disease and Vascular Involvement and is currently actively recruiting participants. Health Institutes of Turkey leads this study, which shows 2 recorded versions since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

2 versions recorded

Sep 2025 — Present [monthly]

Not Yet Recruiting PHASE3
May 2025 — Sep 2025 [monthly]

Not Yet Recruiting PHASE3

First recorded

Apr 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Health Institutes of Turkey
Marmara University

Data source: Marmara University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Istanbul, Turkey (Türkiye)